Skip to main content
. Author manuscript; available in PMC: 2021 Apr 29.
Published in final edited form as: J Med Chem. 2020 Aug 28;63(17):9838–9855. doi: 10.1021/acs.jmedchem.0c01016

Figure 5.

Figure 5.

QD394 is synergistic with select FDA-approved drugs in pancreatic cancer cells. Napabucasin (A), As2O3 (B), and olaparib (C) were added 1 h before QD394. Cells were treated with drugs for 24 h. Red rectangles labeled the wells showing synergy.